      
|
Testosterone Decreases
After Ingestion of Sugar
Click
Here
|
High Glycemic Foods & Beverages are Related to
Low Testosterone Levels
Click
Here
|
Official Legal Claims
Document for
ArgMatrix™
Click Here
|
ArgMatrix™ PASSESS
Independent Analytical
Screening for Steroids
and Illegal Anabolic
Substances.
Official Laboratory
Analytical Documents:
Click Here
|
No
company, other than
Boresha International,
may use
Dr. Ann de Wees Allen's
name on any L-Arginine product.
Click
Here
|
|
L-Arginine
is the Keycode to generating Nitric Oxide in the human body |
 |
|
Boresha International®
announces the introduction of ArgMATRIX™, a State-of-the-Art
L-Arginine Nitric Oxide formula backed by 25-years of research
and a full United States Patent. ArgMATRIX™ contains the
only form of L-Arginine that has been Patented and proven
to be safe long-term in humans.
|
ArgMATRIX™
is the only Patented Edible Computer Chip® that
delivers a specific dose of an Arginine molecule to a targeted
delivery site in the human body. |
| • |
Formulated, researched and Patented by World renowned L-Arginine
researcher, Dr. Ann de Wees Allen® |
| • |
ArgMATRIX™
contains Clinically Proven Levels of safe L-Arginine
|
| • |
ArgMATRIX™
is the only Nitric Oxide L-Arginine product with
2 separate formulas – one specifically designed for the
Female Somatotype and one for the Male Somatotype |
| • |
ArgMATRIX™
is the Key Code for generating Nitric Oxide in
the human body and contains the only Patented L-Arginine
Key Code signaling cell matrix |
| • |
ArgMATRIX™
is Certified Low Glycemic |
| • |
ArgMATRIX™
contains the only proven long-term safe form of L-Arginine,
ArgRX™, which is a unique form of pharmaceutical grade L-Arginine
bound to a Blind Amino Acid Rider. |
| • |
ArgRX™
is the only form of L-Arginine that has been Patented
and proven to be safe long-term in humans, even at very
high doses (50 grams of elemental L-Arginine per day in
humans). |
|
All
forms of L-Arginine require a Blind Amino Acid Rider ®
in order to render arginine safe for use in humans |
|
|
NITRIC OXIDE
Nitric
Oxide (NO) is widely recognized as a key signaling molecule
in human health and is associated with a variety of tissues
and organs that affect cardiovascular disease, inflammatory
disease and male erectile dysfunction.
ARGRX™
research and patents focus on genetically-targeted solutions
for optimal health in humans, including L-Arginine Nitric
Oxide delivery systems. The unique and patented ARGRX™ Nitric
Oxide (NO) transport systems provide a specific signaling
cell matrix designed to achieve appropriate cellular goals
and provide health benefits of NO.
Two
of the Nitric Oxide (NO) patents and formulas, called NO
FOR HEALTH, are exclusively licensed to Boresha International,
and represents one of several technologies that ARGRX™ researchers
developing for delivering NO to target tissues for therapeutic
benefit.
|
|
 |
|
Since its discovery as a signaling molecule
10 years ago, Nitric Oxide (NO) has been demonstrated to
be ubiquitous and essential to a broad range of biological
functions, but potentially dangerous in human use (Johns
Hopkins/JAMA).
ARGRX™ is the only long-term proven safe delivery
system for the amino acid L-Arginine. The patents encompass
the only Nitric Oxide (NO) formulas that contain Blind
Amino Acid® Riders, which render NO and L-Arginine
safe for human use long-term.
|
|
 |
The rate of (Nitric Oxide) NO production
is critically dependent on the bioavailability of Arginine.
NO is a highly reactive, short-lived, lipophilic molecule
with a half life of a few seconds. L-Arginine Nitric Oxide
(NO) formulas are capable of producing excessive NO
or reduced endogenous NO production.
Reduced arginine availability results in reduced NO synthesis.
Arginine availability for NO synthesis is regulated by
de novo arginine synthesis, arginase activity,
and cellular arginine transport. Arginase is generated
by excessive NO levels, and is to be avoided under any
circumstance in an L-Arginine or NO formula.
Excess (excessive) NO creates a toxic environment
in the human body, and low levels of NO (reduced
endogenous NO) are ineffective, so NO highs and lows are
to be avoided. In terms of fertility in males, NO reduces
or inhibits sperm motility, while NOS inhibitors, which
inhibit the formation of NO, prevent the reduction of
sperm motility, indicating a role for the L-arginine-NO
pathway in the modulation of sperm motility and motility
survival.
Sperm motility is negatively affective by both reduced
and excessive endogenous Nitric Oxide (NO). The mechanism
of reduced fertility in males, related to NO,
is a function of the effect of reactive oxygen species
(ROS) on sperm membranes, which depresses sperm function.
Stress also exacerbates reduced motility of sperm. Excessive
NO levels in seminal plasma are associated with poor
sperm quality.
Excessive generation of NO can be toxic and reduce sperm
motility. Further, excessive NO contributes to the formation
of a highly toxic anion of peroxidation, called peroxynitrite.
The unpaired electrons of NO and O2 define peroxynitrite
as a 1-or-2-electron oxidant and nitrating agent, and
not a typical free radical.
Numerous clinical studies have demonstrated that peroxidation
decreases sperm count and motility, and loss of the capacity
of the spermatozoon to undergo the acrosome reaction and
fertilization.
Therefore, NO formulas and products must be produced
under strict GMP manufacturing guidelines utilizing long-term
proven methodologies in L-arginine biochemistry.
The manufacture of NO formulas and products should
not be attempted by persons unfamiliar with L-Arginine
NO toxic byproducts and the Blind Amino Acid
personality of amino acids, such as Arginine.
|
|
 |
ArgMatrix™
contains the
Patented Compound ARGRX™ |
|
ARGRX™
is the only Patented Edible Computer Chip® that delivers
a specific dose of an Arginine molecule to a targeted delivery
site in the human body.
ARGRX™
is the only L-Arginine compound on the market that has undergone
25-years of research to determine Arginine human dosing
guidelines. These specific dosing-guidelines are incorporated
into every ARGRX™ product.
The benefits of ArgRX™ are based on its unique and
patented ability to deliver L-Arginine to site-specific-destinations
in the human body, and produce the following actions:
• |
The
production of Nitric Oxide in elevating serum levels
of Arginine |
• |
Crosses the Blood-Brain-Barrier (BBB) |
• |
Stimulation
of muscle mitochondria |
|
|
 |
| • |
Patented
Pharmaceutical-Grade L-Arginine |
| • |
State-of-the-Art
L-Arginine |
| • |
The only
proven Safe L-Arginine (25 years) |
| • |
L-Arginine
bound to a Blind Amino Acid® Rider |
| • |
Patented
Nitric Oxide Formula |
| • |
The only
Certified Low Glycemic L-Arginine |
| • |
The only
Certified Non-Cephalic L-Arginine |
|
 |
| Essential
to any effective L-Arginine formula, is the ability to deliver
elemental Arginine to targeted sites in the body, utilizing
Threshold Plateau doses.
L-Arginine
benefits are dose and timing-dependent, and reach a Threshold
Plateau at specific elemental doses.
Effective
doses of L-Arginine range from 5,000 mg (5 grams) to 20,000
mg (20 g). Said doses must be ingested at one time.
Time-released
L-Arginine is not effective, as dosages must be
delivered and metabolized in 5-20 gram increments.
L-Arginine
must be administered in humans in elemental form. Elemental
refers to the net dose of an element, and not the gross
weight. Example: Many forms of L-Arginine contain 60 to
80 % pure L-Arginine, and the rest is inert filler. If an
L-Arginine product label represents the gross weight and
not the net weight, the actual amount of L-Arginine is not
represented or known to the consumer.
If
the net dose of deliverable L-Arginine is less than
5 grams of elemental L-Arginine, the product cannot
be considered to be an efficacious L-Arginine formula.
In
calculating doses in L-Arginine products, there are 1000
mg in a gram (g).
|
|
 |
| ARGRX™
is the first L-Arginine complex to contain Embedded Tracer
Technology (ETT). This allows tracking of authentic ARGRX™
products and formulas.
As
an Edible Computer Chip®, ARGRX™ is used as the base of
many different Arginine formulas and products. A Licensing
Agreement is required for any use of ARGRX™ in a product.
Any
formula or product that contains ARGRX™ is required to display
the Official ARGRX™ logo on products and attendant marketing
literature.
|
|
| |
Backed
by United States Patent, Trademarks, and Copyrights.
No part of this website may be copied and placed on another
website, or used for any purpose whatsoever. |
|
These
statements have not been evaluated by the Food & Drug Administration.
The products promoted herein are not intended to diagnose, treat,
cure, or prevent any disease. |
|
